Sarcoma surgery debate: can skipping biopsy track removal reduce harm without raising recurrence risk?
NCT ID NCT07575724
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 4 times
Summary
This study tests whether leaving the needle biopsy track in place during sarcoma surgery is as safe as removing it. The goal is to see if avoiding extra tissue removal can lower complications without increasing the chance of the cancer coming back. About 3,300 people with sarcoma in their arms or legs will take part. The results could change standard surgical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China
-
the Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 311200, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle childhood sarcoma?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?
- Can a Patient's own immune cells fight advanced sarcoma?
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?